Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

Backfill, Etl V1

ID: h-a4e259e0

Hypothesis

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication starts from the claim that modulating CHRNA7 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 CHRNA7🩺 neurodegeneration🎯 Composite 67%💱 $0.55▼23.1%proposed

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease

EvidencePending (0%)📖 23 cit🗣 3 debates✓ 12 support✗ 4 oppose

✓ All Quality Gates Passed

🏆 ChallengeGut Microbial Metabolites as Early Causal Drivers of Alzheimer's Pathogenesis$1.8M →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite67%

🧪 Overview

Mechanistic Overview

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication starts from the claim that modulating CHRNA7 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Gut dysbiosis disrupts vagal cholinergic anti-inflammatory pathways by reducing acetylcholine-producing bacteria and damaging enteric neurons. Vagus nerve stimulation combined with choline supplementation could restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression.

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

...

Mechanistic Overview

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication starts from the claim that modulating CHRNA7 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "Gut dysbiosis disrupts vagal cholinergic anti-inflammatory pathways by reducing acetylcholine-producing bacteria and damaging enteric neurons. Vagus nerve stimulation combined with choline supplementation could restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression.

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

The vagus nerve serves as the primary bidirectional communication highway between the gut and the brain, carrying both afferent (gut-to-brain) sensory signals and efferent (brain-to-gut) motor and autonomic commands. The cholinergic anti-inflammatory pathway (CAP) is a critical neural circuit in which efferent vagal signals suppress peripheral inflammation through acetylcholine (ACh) release. This pathway was first characterized by Kevin Tracey and colleagues, who demonstrated that electrical stimulation of the vagus nerve could dramatically reduce systemic TNF-alpha levels during endotoxemia — an effect mediated entirely by acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChR) expressed on macrophages and other immune cells. The circuit operates as follows: inflammatory signals from the gut (cytokines, pathogen-associated molecular patterns) activate vagal afferent neurons in the nodose ganglion, which relay to the nucleus tractus solitarius (NTS) in the brainstem. The NTS projects to the dorsal motor nucleus of the vagus (DMV), which sends efferent cholinergic signals back to the gut via the vagus nerve. In the gut, these efferent fibers synapse on enteric neurons in the myenteric and submucosal plexuses, which in turn release acetylcholine that activates α7nAChR on resident macrophages, dendritic cells, and innate lymphoid cells. Activation of α7nAChR triggers the JAK2-STAT3 signaling cascade in these immune cells, which suppresses NF-kB-dependent transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, HMGB1) while preserving anti-inflammatory cytokine production (IL-10).

Gut Dysbiosis and Cholinergic Pathway Disruption in Neurodegeneration

Multiple lines of evidence connect gut dysbiosis to impaired vagal cholinergic signaling in Parkinson's disease and Alzheimer's disease: Reduced acetylcholine-producing bacteria: The gut microbiome includes several bacterial species capable of synthesizing acetylcholine via choline acetyltransferase homologs, including Lactobacillus plantarum, Bacillus subtilis, and certain Clostridium species. Metagenomic analyses of PD patient stool samples consistently show reduced abundance of these species, with a corresponding decrease in fecal acetylcholine levels. This microbial ACh contributes to local mucosal immune regulation and amplifies the vagal cholinergic signal — its loss creates a deficit that cannot be fully compensated by neuronal ACh alone. Enteric neuron damage: Alpha-synuclein aggregates, the pathological hallmark of PD, are found in enteric neurons of the gut plexuses years to decades before they appear in the brain. The "Braak hypothesis" proposes that PD pathology originates in the gut and propagates to the brain via the vagus nerve. These enteric alpha-synuclein aggregates impair enteric neuron function, reducing both the ACh output of cholinergic enteric neurons and the relay capacity of the enteric nervous system. Damaged enteric neurons also release inflammatory mediators that further disrupt mucosal barrier integrity. Vagal tone reduction: PD patients show reduced heart rate variability (HRV), a clinical measure of vagal tone, even in prodromal stages. Reduced vagal tone means reduced efferent cholinergic signaling to the gut, weakening the anti-inflammatory reflex. This creates a feed-forward cycle: gut inflammation damages enteric neurons, which impairs vagal signaling, which reduces cholinergic anti-inflammatory tone, which permits more inflammation. Intestinal barrier disruption: Gut dysbiosis in PD is associated with increased intestinal permeability ("leaky gut"), allowing bacterial endotoxins (lipopolysaccharide, LPS) and inflammatory mediators to enter the systemic circulation. Chronic low-grade endotoxemia activates systemic and central immune responses, with LPS crossing the blood-brain barrier and directly activating microglial TLR4 receptors, promoting neuroinflammation in substantia nigra and other vulnerable brain regions.

The α7nAChR Node: Where Vagal Signaling Meets Immune Regulation

The alpha-7 nicotinic acetylcholine receptor (α7nAChR, encoded by CHRNA7) is the critical effector of the cholinergic anti-inflammatory pathway. On macrophages and microglia, α7nAChR activation: 1. Inhibits the NLRP3 inflammasome: ACh binding to α7nAChR activates the Nrf2 antioxidant pathway and inhibits mitochondrial ROS production, preventing the assembly of the NLRP3 inflammasome complex and reducing IL-1β and IL-18 processing and secretion. 2. Suppresses NF-kB translocation: α7nAChR signaling through JAK2-STAT3 induces expression of SOCS3 (Suppressor of Cytokine Signaling 3), which inhibits NF-kB nuclear translocation and thus reduces transcription of TNF-α, IL-6, and other pro-inflammatory genes. 3. Promotes phagocytic clearance: In microglia, α7nAChR activation enhances phagocytosis of amyloid-beta and alpha-synuclein aggregates while maintaining an anti-inflammatory phenotype — effectively promoting "silent" phagocytosis without the cytokine storm that accompanies FcR-mediated or complement-mediated uptake. 4. Supports BBB integrity: α7nAChR on brain endothelial cells maintains tight junction integrity and reduces BBB permeability. Cholinergic deficiency increases BBB leakage, allowing peripheral immune cells and inflammatory mediators to infiltrate the brain parenchyma.

Therapeutic Strategy: Dual Vagal-Nutritional Intervention

The proposed intervention combines vagus nerve stimulation (VNS) with targeted choline supplementation to restore the cholinergic anti-inflammatory pathway from both ends:

Vagus Nerve

Stimulation (VNS) Non-invasive transcutaneous VNS (tVNS) devices stimulate the auricular branch of the vagus nerve through the ear, activating the same brainstem nuclei as surgical VNS without requiring implantation. tVNS has shown anti-inflammatory effects in clinical studies: - Reduces plasma TNF-α, IL-6, and CRP in healthy volunteers and patients with rheumatoid arthritis - Increases heart rate variability, reflecting enhanced vagal tone - Reduces microglial activation markers in neuroimaging studies (TSPO-PET) - Currently in Phase 2 trials for PD (NCT04381936) and AD (NCT04908358) The key advantage of tVNS is that it bypasses the damaged enteric neurons, directly activating the central vagal circuit. This is important because in PD, the enteric nervous system is already compromised by alpha-synuclein pathology — stimulating the vagus centrally can restore efferent cholinergic output even when afferent relay from the gut is impaired.

Choline Supplementation

Choline is the essential precursor for acetylcholine synthesis. Citicoline (CDP-choline) and alpha-GPC (alpha-glycerophosphocholine) are bioavailable choline sources that cross the blood-brain barrier and increase both central and peripheral ACh levels: - Citicoline: Has neuroprotective properties beyond cholinergic support, including membrane stabilization and dopamine synthesis enhancement. Meta-analyses show cognitive benefits in vascular dementia and post-stroke patients. It also serves as a precursor for phosphatidylcholine synthesis, supporting neuronal membrane repair. - Alpha-GPC: More rapidly increases plasma and brain ACh levels than other choline sources. Phase 3 trials in AD (Gliatilin) showed benefits in cognitive endpoints, though methodological quality was limited. The combined approach addresses a critical limitation of each monotherapy: VNS alone increases vagal firing but may be limited by insufficient ACh substrate availability, while choline supplementation alone cannot overcome the impaired vagal relay in patients with enteric neuron damage.

Probiotic Adjunct: Restoring Microbial ACh Production

The intervention could be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains. Lactobacillus plantarum PS128, which has shown anti-inflammatory and neuroprotective effects in PD mouse models, produces ACh and also modulates serotonin and dopamine metabolism. Clinical trials of PS128 in PD patients have shown improvements in motor symptoms and quality of life.

Preclinical Evidence

Vagotomy studies: Truncal vagotomy in rodents abolishes the cholinergic anti-inflammatory reflex, leading to exaggerated gut inflammation and accelerated alpha-synuclein propagation to the brain. Conversely, epidemiological studies have shown that patients who underwent truncal vagotomy have a 40-50% reduced risk of PD — seemingly paradoxical, but explained by the interruption of retrograde alpha-synuclein transport from gut to brain. VNS in PD models: In rotenone and 6-OHDA PD models, chronic VNS reduces dopaminergic neuron loss in substantia nigra by 30-50%, decreases microglial activation, and improves motor performance. The neuroprotective effect is abolished by α7nAChR antagonists (mecamylamine), confirming that it operates through the cholinergic anti-inflammatory pathway. Germ-free mouse studies: Germ-free mice show reduced enteric and central cholinergic tone, with decreased ACh levels in both the gut and brain. Colonization with ACh-producing bacteria (L. plantarum) restores cholinergic signaling and reduces neuroinflammation in response to LPS challenge.

Evidence For This Hypothesis -

Vagus nerve stimulation reduces neuroinflammation and protects dopaminergic neurons in PD mouse models (Farrand et al., Brain Stimulation 2017) - PD patients show reduced vagal tone (HRV) even in prodromal stages (Postuma et al., Brain 2012) - α7nAChR agonists suppress microglial activation and protect against neurodegeneration in vitro and in vivo (Shytle et al., J Neuroinflammation 2004) - Gut dysbiosis in PD includes reduced ACh-producing bacteria (Sampson et al., Cell 2016) - Truncal vagotomy epidemiological data supports gut-brain vagal involvement in PD (Svensson et al., Ann Neurol 2015) - tVNS clinical trials in PD and AD show anti-inflammatory biomarker responses (Badran et al., Brain Stimulation 2022)

Evidence Against This Hypothesis -

The vagotomy-PD risk reduction is inconsistent across epidemiological cohorts, with some studies finding no effect (Tysnes et al., Ann Neurol 2015) - tVNS effects on neuroinflammation may be transient and require continuous or chronic stimulation to be clinically meaningful - Choline supplementation alone has not shown consistent cognitive benefits in large-scale AD/PD trials - The "Braak hypothesis" of gut-origin PD pathology remains debated; not all PD patients show prodromal GI symptoms - Restoring cholinergic signaling may be insufficient if enteric neuron damage from alpha-synuclein is irreversible" Framed more explicitly, the hypothesis centers CHRNA7 within the broader disease setting of neurodegeneration. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `neuroinflammation`.

SciDEX scoring currently records confidence 0.50, novelty 0.80, feasibility 0.70, impact 0.70, mechanistic plausibility 0.60, and clinical relevance 0.33.

Molecular and Cellular Rationale

The nominated target genes are `CHRNA7` and the pathway label is `Vagal cholinergic anti-inflammatory pathway (α7nAChR)`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: CHRNA7 (α7nAChR) expression is reduced in substantia nigra microglia and enteric neurons in PD post-mortem tissue. Vagal motor neurons in the dorsal motor nucleus show alpha-synuclein pathology and reduced choline acetyltransferase (ChAT) expression in early PD stages, consistent with impaired cholinergic output.
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Identifies CHRNA7 nodes as potential signals in cognitive decline, suggesting cholinergic pathway involvement. ^[1].

Demonstrates nicotinic acetylcholine receptors can modulate immune cytokine release, supporting anti-inflammatory mechanisms. ^[2].

Shows nicotinic acetylcholine receptors can modulate immune functions of human phagocytes. ^[3].

Highlights alpha 7 nicotinic acetylcholine receptor's role in neurological recovery. ^[4].

Demonstrates how diet impacts cholinergic signaling and neuroinflammation. ^[5].

The paper explores α7-nicotinic acetylcholine receptor function in astrocytes, which aligns with the hypothesis's focus on α7nAChR's role in neural signaling and inflammation. ^[6].

Contradictory Evidence, Caveats, and Failure Modes

Clinical trials of α7nAChR agonists (encenicline, ABT-126) in AD showed no significant cognitive benefit over placebo. ^[7].

Truncal vagotomy reduces PD risk, but this may reflect reduced α-synuclein propagation rather than anti-inflammatory effects. ^[8].

Vagus nerve stimulation effects on neuroinflammation are transient and may not provide sustained neuroprotection. ^[9].

Vagus Nerve Stimulation and the Cardiovascular System. ^[10].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.701`, debate count `3`, citations `23`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: Recruiting.

Trial context: Completed.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates CHRNA7 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting CHRNA7 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

graph TD
    A["Gut Dysbiosis<br/>Reduced ACh-producing bacteria<br/>Pathobiont overgrowth"] --> B["Enteric Neuron Damage<br/>Loss of cholinergic neurons<br/>Reduced local ACh synthesis"]
    A --> C["Increased Gut Permeability<br/>LPS translocation<br/>PAMP release"]
    
    B --> D["Impaired Vagal Afferent<br/>Signaling<br/>Reduced gut-brain communication"]
    C --> E["Intestinal Macrophage<br/>Activation<br/>Pro-inflammatory phenotype"]
    
    D --> F["Nucleus Tractus Solitarius<br/>NTS<br/>Reduced inflammatory sensing"]
    E --> G["Systemic Inflammation<br/>TNF-alpha and IL-1beta<br/>elevation"]
    
    F --> H["Dorsal Motor Nucleus<br/>DMV<br/>Decreased efferent output"]
    G --> I["Blood-Brain Barrier<br/>Disruption<br/>Neuroinflammation initiation"]
    
    H --> J["Efferent Vagal<br/>Cholinergic Output<br/>Reduced ACh release"]
    I --> K["Microglial Activation<br/>Neuroinflammatory cascade<br/>Oxidative stress"]
    
    J --> L["Splenic Nerve Terminal<br/>ACh release to<br/>sympathetic ganglia"]
    K --> M["Alpha-Synuclein<br/>Aggregation<br/>Protein misfolding"]
    
    L --> N["Splenic T-Cell Activation<br/>CD4+ T-cells release<br/>ACh and norepinephrine"]
    M --> O["Dopaminergic Neuron<br/>Degeneration<br/>Substantia nigra loss"]
    
    N --> P["Macrophage CHRNA7<br/>Binding<br/>Anti-inflammatory signaling"]
    O --> Q["Parkinsonian Motor<br/>Symptoms<br/>Disease progression"]
    
    P --> R["JAK2-STAT3 Inhibition<br/>Suppressed NF-kappaB<br/>Reduced cytokine production"]
    
    S["Vagus Nerve Stimulation<br/>VNS therapy<br/>Electrical activation"] --> H
    T["Choline Supplementation<br/>Dietary intervention<br/>ACh precursor loading"] --> J
    U["Targeted CHRNA7<br/>Agonist Therapy<br/>Direct receptor activation"] --> P
    
    R --> V["Restored Anti-Inflammatory<br/>Balance<br/>Neuroprotective environment"]
    V --> W["Therapeutic Outcome<br/>Slowed neurodegeneration<br/>Improved motor function"]

    classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
    classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
    classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
    classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
    classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a

    class A,B,C,D,E pathology
    class F,G,H,I,J normal
    class K,L,M,N,O pathology
    class P,R,V molecular
    class Q outcome
    class S,T,U therapeutic
    class W outcome

⚖️ Evidence

⚖️ Evidence Matrix12 supports4 contradicts

Supports

Identifies CHRNA7 nodes as potential signals in cognitive decline, suggesting cholinergic pathway involvement.

Mol Nutr Food Res2026PMID:41663888medium

Abstract

Emerging evidence suggests that chronic use of gastric acid-suppressing medications may contribute to neurocognitive decline, yet the underlying mechanisms remain poorly defined. Proton pump inhibitors like omeprazole and histamine-2 receptor antagonists such as ranitidine are widely prescribed for gastrointestinal disorders, but their long-term impact on brain function. Forty-eight male Wistar rats were assigned to six groups receiving either control diet, B12 alone, omeprazole, ranitidine, or

Supports

Demonstrates nicotinic acetylcholine receptors can modulate immune cytokine release, supporting anti-inflammatory mechanisms.

Front Immunol2025PMID:41221292medium

Abstract

The clinical interest in mechanisms controlling the biosynthesis and release of the pro-inflammatory cytokine interleukin (IL)-1β is outstanding, as IL-1β is associated with life-threatening inflammatory diseases including hyperinflammation caused by extracellular ATP originating from damaged cells. Previously, we identified a cholinergic mechanism controlling ATP-dependent IL-1β release via metabotropic signaling of unconventional nicotinic acetylcholine receptors (nAChRs) containing subunits α

Supports

Shows nicotinic acetylcholine receptors can modulate immune functions of human phagocytes.

Front Immunol2026PMID:41890755medium

Abstract

Nicotinic acetylcholine receptors (nAChRs) on immune cells are promising therapeutic targets for the treatment of inflammatory diseases and pain. Both α7 and α9* nAChRs (*denotes the potential presence of other nAChR subunits) have been implicated as mediators of the cholinergic anti-inflammatory system (CAS). This study investigated the binding sites of α7-selective ligands on these receptors and their effects on ATP-dependent release of the pro-inflammatory cytokines interleukin (IL)-1β and IL

Supports

Highlights alpha 7 nicotinic acetylcholine receptor's role in neurological recovery.

Exp Neurol2026PMID:41270982medium

Abstract

Stroke is associated with autonomic dysfunction and reduced acetylcholine (ACh), a neurotransmitter critical for cognition. ACh signals in part through the alpha-7 nicotinic acetylcholine receptor (α7nAChR), a ligand-gated ion channel involved in synaptic plasticity, learning, and memory. Impaired α7nAChR signaling has been linked to heightened neuroinflammation and poor acute stroke recovery. Here, we investigated whether α7nAChR contributes to post-stroke cognitive recovery in young male mice.

Supports

Demonstrates how diet impacts cholinergic signaling and neuroinflammation.

J Nutr Biochem2026PMID:41565126medium

Abstract

Consumption of a high-fat diet (HFD) can lead to cognitive dysfunction and neuroinflammation in the hippocampus, particularly the CA3 region, which is vital for associative memory. Cholinergic input from the basal forebrain to the hippocampus is critical for regulating excitability, plasticity, and overall cognitive function in this area. Neuroinflammation may disrupt the expression of the α7 nicotinic acetylcholine receptor (α7nAChR), essential for the anti-inflammatory cholinergic pathway. We

Supports

The paper explores α7-nicotinic acetylcholine receptor function in astrocytes, which aligns with the hypothesis's focus on α7nAChR's role in neural signaling and inflammation.

Neurobiol Dis2026PMID:41453579medium

Abstract

The astrocyte-neuron network in the primary somatosensory cortex (S1) responds dynamically to pain stimuli and plays a pivotal role in pain processing. These stimuli activate astrocytic α7-nicotinic acetylcholine receptors (α7-nAChRs), yet their contribution to pain perception remains largely unclear. This study investigates the role of astrocytic α7-nAChRs in pain information processing and perception. Astrocytic α7-nAChRs were selectively deleted by injecting rAAV5-GfaABC1D-NLS-Cre-P2A-mCherry

Supports

The paper demonstrates α7 nicotinic acetylcholine receptor involvement in cellular signaling pathways, supporting the hypothesis's focus on cholinergic receptor mechanisms.

Int J Biol Sci2026PMID:41608625medium

Abstract

Recent studies have extensively addressed the potential role of the autonomic nervous system, which extensively innervates the pancreas, in the development of pancreatic ductal adenocarcinoma (PDAC). Targeting hypoxia-inducible factor-1 (HIF-1) for cancer management has attracted significant research interest, in view of the finding that HIF-1 regulates the expression of various genes involved in tumor angiogenesis, metastasis, proliferation, chemoresistance, and radioresistance. In this study,

Supports

Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.

Mol Psychiatry2025PMID:40610703medium

Abstract

Psychological stress plays a critical role in the onset of depression by activating neuroimmune and endocrine responses, leading to dysregulation of the hypothalamic-pituitary-adrenal axis and increased inflammation. This imbalance impacts key brain regions involved in mood regulation, such as the p

Supports

Unilateral Cervical Vagotomy Modulates Immune Cell Profiles and the Response to a Traumatic Brain Injury.

Int J Mol Sci2022PMID:36077246medium

Abstract

TBI induces splenic B and T cell expansion that contributes to neuroinflammation and neurodegeneration. The vagus nerve, the longest of the cranial nerves, is the predominant parasympathetic pathway allowing the central nervous system (CNS) control over peripheral organs, including regulation of inf

Supports

Vagus nerve stimulation as a promising neuroprotection for ischemic stroke via α7nAchR-dependent inactivation of microglial NLRP3 inflammasome.

Acta Pharmacol Sin2024PMID:38504011medium

Abstract

Ischemic stroke is a major cause of disability and death worldwide, and its management requires urgent attention. Previous studies have shown that vagus nerve stimulation (VNS) exerts neuroprotection in ischemic stroke by inhibiting neuroinflammation and apoptosis. In this study, we evaluated the ti

Supports

α7 Nicotinic Acetylcholine Receptor Signaling Modulates Ovine Fetal Brain Astrocytes Transcriptome in Response to Endotoxin.

Front Immunol2019PMID:31143190medium

Abstract

Neuroinflammation

Supports

Nicotine Suppresses Human Memory Th Cell Subsets With Preferential Effects on Central Memory Th Cells in an α7 Nicotinic Acetylcholine Receptor-Dependent Manner.

Eur J Immunol2026PMID:41928597

Contradicts

Clinical trials of α7nAChR agonists (encenicline, ABT-126) in AD showed no significant cognitive benefit over placebo

Lancet Neurol2017PMID:28763068strong

Abstract

Atrioventricular septal defects are a wide spectrum of cardiac malformations, from partial until complete with one unique atrioventricular valve, atrioventricular valve communication, and leaky left heart valve. Its fast evolution to pulmonary vascular disease calls for early surgical management. Corrective treatment has a high percentage of re-operations and 8.6% mortality. To describe the results of corrective treatments of atrioventricular septum defects in our institution's patients. Observa

Contradicts

Truncal vagotomy reduces PD risk, but this may reflect reduced α-synuclein propagation rather than anti-inflammatory effects

Ann Neurol2015PMID:27479119medium

Abstract

The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited.

Contradicts

Vagus nerve stimulation effects on neuroinflammation are transient and may not provide sustained neuroprotection

Brain Stimul2019PMID:31234192medium

Contradicts

Vagus Nerve Stimulation and the Cardiovascular System.

Cold Spring Harb Perspect Med2020PMID:31109966medium

Abstract

The vagus nerve plays an important role in maintaining physiological homeostasis, which includes reflex pathways that regulate cardiac function. The link between vagus nerve activity and the high-frequency component of heart rate variability (HRV) has been well established, correlating with vagal to

📖 Linked Papers (24)Export BibTeX ↗

Bi-allelic loss of function variants in SLC30A5 as cause of perinatal lethal cardiomyopathy.

European journal of human genetics : EJHG (2021) · PubMed:33547425 ↗

2 figures

Fig. 1

Overview on individuals. The figure lists key information on all affected individuals including variant postions. The conventional symbols were used for the ped...

Fig. 2

Imaging findings of the affected individuals. Prenatal ultrasound scans at the level of four-chamber view of individuals of family 1 ( A : Voluson S8, AB2-7 con...

Predicting Subjective Recovery from Lower Limb Surgery Using Consumer Wearables.

Digital biomarkers (2020) · PubMed:33442582 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Environmental Regulation, Technological Innovation, and Export Competitiveness: An Empirical Study Based on China's Manufacturing Industry.

International journal of environmental research and public health (2020) · PubMed:32102174 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Nicotine Suppresses Human Memory Th Cell Subsets With Preferential Effects on Central Memory Th Cells in an α7 Nicotinic Acetylcholine Receptor-Dependent Manner.

Eur J Immunol (2026) · PubMed:41928597 ↗

No figures

Putative α7-selective ligands interact with α9-containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytes.

Frontiers in immunology (2026) · PubMed:41890755 ↗

No figures

Signal-Level Determinants of Cognitive Decline With PPIs versus H2RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.

Molecular nutrition & food research (2026) · PubMed:41663888 ↗

No figures

Acetylcholine enhances HIF-1α signaling in pancreatic cancer cells under hypoxia through the nAChR-α7/PDPK1/YAP pathway.

International journal of biological sciences (2026) · PubMed:41608625 ↗

No figures

Short-term exposure to a high-fat diet leads to neuroinflammation and impairs memory and cholinergic signaling in the hippocampal CA3 region of male mice.

The Journal of nutritional biochemistry (2026) · PubMed:41565126 ↗

No figures

Astrocytic α7-nicotinic acetylcholine receptors mediate pain information processing and perception.

Neurobiology of disease (2026) · PubMed:41453579 ↗

No figures

Alpha 7 nicotinic acetylcholine receptor contributes to long-term cognitive recovery following ischemic stroke.

Experimental neurology (2026) · PubMed:41270982 ↗

No figures

The ATP-mediated cytokine release by macrophages is down-modulated by unconventional α9* nicotinic acetylcholine receptors.

Frontiers in immunology (2025) · PubMed:41221292 ↗

No figures

Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.

Molecular psychiatry (2025) · PubMed:40610703 ↗

No figures

📙 Related Wiki Pages (15)

Neurofilament Light Chain (NF-L)protein Parkin Proteinprotein NfL-Guided Neuroprotection Thresholdidea NEFL Genegene Neurofilament Light Chain (NfL) - Biomarbiomarker Neurofilament Light Chain (NfL) in Bloodbiomarker NES Proteinprotein Nicotinic Receptor Alpha 7 Proteinprotein Neurodegenerationdisease Alibaba Tongyi Qianwen-Bio (Chinese Biomai_tool CHRNA7 Genegene Enteric Neuronscell Blood-Brain Barriercell Dorsal Motor Nucleus of the Vaguscell Endothelial Cellscell

🏥 Translation

🧬 3D Protein Structure — CHRNA7

🧬 PDB 7KOO Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for CHRNA7 from GTEx v10.

💉 Clinical Trials (3)Relevance: 33%

2
Active

1
Completed

0
Total Enrolled

Phase 2
Highest Phase

Untitled TrialPhase 2

Recruiting· · Academic

Untitled TrialPhase 2

Recruiting· · Academic

Untitled TrialPhase 2

Completed· · Bened Biomedical

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for CHRNA7 →

No DepMap CRISPR Chronos data found for CHRNA7.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

18 months

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 2.9%

Volatility

Low

0.0056

Events (7d)

5

Price History

▼23.1%

💾 Resource Usage

LLM Tokens

40,932

$0.2456

Total Cost

$0.2456

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
If hypothesis is true, intervention restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression	restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression	— no observation —	pending	0.50
If hypothesis is true, intervention be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains	be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains	— no observation —	pending	0.50

🔮 Falsifiable Predictions (2)

pendingconf 50%

If hypothesis is true, intervention restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

Predicted outcome: restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

Falsification: Intervention fails to restore this protective pathway and reduce systemic inflammation driving Parkinson's disease progression

pendingconf 50%

If hypothesis is true, intervention be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

Predicted outcome: be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

Falsification: Intervention fails to be further enhanced by probiotic supplementation with acetylcholine-producing bacterial strains

📖 References (10)

Signal-Level Determinants of Cognitive Decline With PPIs versus H2RAs: Transportome (CBLIF/TCN2) and CHRNA7 Nodes.
Saihati HAA et al.. Molecular nutrition & food research (2026)
PubMed↗DOI↗
The ATP-mediated cytokine release by macrophages is down-modulated by unconventional α9* nicotinic acetylcholine receptors.
Wolf PMK et al.. Frontiers in immunology (2025)
PubMed↗DOI↗
Putative α7-selective ligands interact with α9-containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytes.
Mobasher M et al.. Frontiers in immunology (2026)
PubMed↗DOI↗
Alpha 7 nicotinic acetylcholine receptor contributes to long-term cognitive recovery following ischemic stroke.
Nguyen DT et al.. Experimental neurology (2026)
PubMed↗DOI↗
Short-term exposure to a high-fat diet leads to neuroinflammation and impairs memory and cholinergic signaling in the hippocampal CA3 region of male mice.
Costa SO et al.. The Journal of nutritional biochemistry (2026)
PubMed↗DOI↗
Astrocytic α7-nicotinic acetylcholine receptors mediate pain information processing and perception.
Teng T et al.. Neurobiology of disease (2026)
PubMed↗DOI↗
Experience in the corrective treatment of patients with atrioventricular septum.
Olivares-Fernández Y et al.. Gaceta medica de Mexico (2017)
PubMed↗
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Worst BC et al.. European journal of cancer (Oxford, England : 1990) (2016)
PubMed↗DOI↗
Insights image for vitamin D binding protein polymorphisms significantly impact vitamin D status in children.
Newton Danforth A; Baatz John E; Kindy Mark S; Gattoni-Celli Sebastiano; Shary Judy R; Hollis Bruce W; Wagner Carol L. Pediatric research (2019)
PubMed↗DOI↗
Vagus Nerve Stimulation and the Cardiovascular System.
Capilupi MJ et al.. Cold Spring Harbor perspectives in medicine (2020)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		67%
Mech.		60%
Evidence		50%
Novelty		80%
Feasibility		70%
Impact		70%
Druggability		60%
Safety		80%
Competition		70%
Data avail.		60%
Reproducibility		60%

📗 Cite This Artifact

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

🧪 Overview

Mechanistic Overview

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

Mechanistic Overview

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

Gut Dysbiosis and Cholinergic Pathway Disruption in Neurodegeneration

The α7nAChR Node: Where Vagal Signaling Meets Immune Regulation

Therapeutic Strategy: Dual Vagal-Nutritional Intervention

Vagus Nerve

Choline Supplementation

Probiotic Adjunct: Restoring Microbial ACh Production

Preclinical Evidence

Evidence For This Hypothesis -

Evidence Against This Hypothesis -

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — CHRNA7

💉 Clinical Trials (3)Relevance: 33%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (10)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication

🧪 Overview

Mechanistic Overview

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

Mechanistic Overview

The Cholinergic Anti-Inflammatory Pathway: A Gut-Brain Immune Circuit

Gut Dysbiosis and Cholinergic Pathway Disruption in Neurodegeneration

The α7nAChR Node: Where Vagal Signaling Meets Immune Regulation

Therapeutic Strategy: Dual Vagal-Nutritional Intervention

Vagus Nerve

Choline Supplementation

Probiotic Adjunct: Restoring Microbial ACh Production

Preclinical Evidence

Evidence For This Hypothesis -

Evidence Against This Hypothesis -

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — CHRNA7

💉 Clinical Trials (3)Relevance: 33%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (5)

associated with (4)

causes (12)

encodes (1)

enhances (1)

generated (5)

inhibits (4)

investigated in (2)

modulates (6)

produces (2)

protective against (1)

reduces (1)

regulates (4)

risk factor for (2)

🔮 Predictions

📖 References (10)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion